Extracorporeal photopheresis in prevention and treatment of acute GVHD

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
Carrie L Kitko, John E Levine

Abstract

Acute graft versus host disease (GVHD), a common complication after allogeneic hematopoietic cell transplantation (HCT), occurs in as many as 70% of recipients of this life saving treatment. Front line therapy for GVHD with corticosteroids will fail in up to 40% of patients, which leads to high morbidity and mortality. Traditional prevention and treatment strategies have focused on reducing alloreactivity, typically with therapy to reduce cytotoxic T-cell function. Emerging evidence exists that promotion of regularly T-cell function, through treatments such as extracorporeal photopheresis, is effective for GVHD treatment and has potential for prevention as well. This review will focus on literature reporting the success of ECP for steroid refractory acute GVHD and the potential for delivery of ECP in the early pre and post-transplant periods that shows promise as a less immunosuppressive strategy to reduce rates of acute GVHD.

References

Apr 2, 1998·The New England Journal of Medicine·J A HansenC Anasetti
Aug 5, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R Mitsuyasu
Feb 9, 2000·The Journal of Experimental Medicine·R M SteinmanK Inaba
Mar 22, 2000·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·R N BarkerA J Rees
Apr 17, 2003·Journal of Endotoxin Research·Kenneth R CookeJames L M Ferrara
Oct 15, 2003·Blood Reviews·Pavan Reddy, James L M Ferrara
Mar 5, 2005·Blood·Manuela BattagliaMaria-Grazia Roncarolo
Jun 29, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohamed L SorrorRainer Storb
Sep 27, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohamed L SorrorRainer Storb
Oct 4, 2005·Immunology Letters·Guillaume Darrasse-JèzeJosé L Cohen
Jun 25, 2008·Bone Marrow Transplantation·E CaloreC Messina
Jul 29, 2008·Bone Marrow Transplantation·P PerfettiA Bacigalupo
Nov 11, 2008·Bone Marrow Transplantation·R RamO Shpilberg
Mar 14, 2009·Lancet·James L M FerraraErnst Holler
Mar 23, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John M MagenauSophie Paczesny
Aug 9, 2011·Seminars in Immunology·Keli L HippenBruce R Blazar
Dec 2, 2011·The New England Journal of Medicine·John KorethRobert J Soiffer
Apr 19, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul J MartinPaul A Carpenter
Apr 30, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Madan JagasiaGerard Socie
Dec 10, 2013·The Journal of Pediatrics·Frank DiPaolaJohn Bucuvalas

❮ Previous
Next ❯

Citations

Aug 12, 2015·Current Opinion in Organ Transplantation·Robin VosGeert M Verleden
Jan 1, 2016·Expert Opinion on Orphan Drugs·Anne S RenteriaJames L M Ferrara
Dec 22, 2020·Terapevticheskiĭ arkhiv·L A KuzminaV G Savchenko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.